Vagisil

Vagisil is an American over-the-counter intimate-care brand produced by Combe Incorporated, a personal-care company headquartered in White Plains, New York. The brand was introduced in 1974 and became associated primarily with topical products intended to relieve external vulvar itching and irritation. Its best-known cream formulation uses benzocaine as a local anesthetic to reduce the sensation of itching and resorcinol as an antiseptic intended to address irritated skin. Vagisil is therefore positioned at the intersection of consumer healthcare, feminine hygiene, and personal care rather than as a prescription pharmaceutical brand. The brand's traditional proposition has been immediate, accessible symptom relief for external discomfort. Its products are sold as over-the-counter remedies, allowing consumers to purchase them without a prescription. The distinction between external vulvar symptoms and internal vaginal conditions is important to the brand's category: Vagisil products are not presented as universal treatments for every cause of genital discomfort, and medical commentators have warned that symptoms such as itching can have causes that require professional diagnosis, including infections that should not be self-treated with an anti-itch product. Vagisil expanded beyond its established cream category in February 2021 with the OMV! line. The range included scented wipes, cleansers, and anti-itch creams for use around the vulvar area. The launch was marketed toward teenagers and younger consumers, broadening the brand's communication from symptom relief toward period hygiene, odor concerns, cleansing, and everyday intimate care. This represented a notable change in positioning: rather than focusing only on an acute discomfort, the brand also addressed lifestyle and personal-care concerns. The OMV! launch generated criticism from physicians and other commentators on social media. Obstetrician-gynecologists Jen Gunter, Chavone Momon-Nelson, and Jocelyn Fitzgerald expressed concern that scented intimate-care marketing could make teenagers feel ashamed of their bodies, cause irritation or allergic reactions, and encourage consumers to delay medical care for conditions requiring diagnosis. They also questioned the premise that the vagina requires special cleansing or fragrance. Vagisil responded that OMV! products were formulated with an appropriate pH for external vulvar use and had been evaluated by independent dermatologists and gynecologists. The company also said the products were developed in response to concerns voiced by active young women about period hygiene and odor, while acknowledging that the products were not suitable for everyone. Vagisil has also appeared in popular culture, including comedy sketches and television episodes that use its intimate-care category as a source of humor. These appearances have increased the brand's cultural recognizability, although they are not evidence of additional corporate activity or product performance. The brand remains associated with Combe's consumer-health portfolio and with nonprescription products for external intimate discomfort and hygiene.

Vagisil was introduced in 1974 as an American over-the-counter brand for external vulvar itching and irritation. It was developed and commercialized by Combe Incorporated, the White Plains, New York-based company behind the brand. Its traditional identity centered on a topical cream rather than a broad range of intimate-care products. The cream's documented active ingredients are benzocaine at a 5 percent concentration and resorcinol at a 2 percent concentration. Benzocaine functions as a local anesthetic that reduces the perception of itching, while resorcinol is used as an antiseptic for irritated skin. The brand's consumer-health positioning made it a readily available option for people experiencing external discomfort. At the same time, the category requires a distinction between temporary symptom relief and diagnosis of an underlying condition. Vagisil became known as a product for external symptoms, not as a general treatment for every vaginal or vulvar complaint. This distinction was particularly relevant during later debates about the brand's marketing and the risk that consumers might use an anti-itch product when professional assessment was more appropriate. A significant expansion occurred in February 2021, when Vagisil launched OMV!. The range included scented wipes, cleansers, and anti-itch creams designed for external vulvar use. The launch targeted teenagers and emphasized concerns such as period hygiene and odor, moving the brand beyond its historic association with an anti-itch cream and into broader intimate hygiene and lifestyle personal care. The OMV! campaign provoked public criticism from physicians active on social media. Jen Gunter, Chavone Momon-Nelson, and Jocelyn Fitzgerald raised concerns that fragrance-oriented messaging could imply that normal bodies require refreshing or concealment. They also warned that scented products could contribute to irritation or allergic reactions and that consumers might mistake symptoms of conditions such as yeast infections for problems suitable for self-treatment. Gunter and Momon-Nelson argued that the vagina does not need special cleansing and that menstruation is a natural process rather than an odor problem requiring fragrance. Vagisil defended the products by stating that they were formulated at an appropriate pH for the external vulvar area and had been tested by independent dermatologists and gynecologists. A company spokesperson said OMV! was created in response to concerns expressed by young, active women about period hygiene and odors, while also noting that the products were not intended for everyone. The exchange became an example of the wider debate over intimate-care advertising: whether such products provide useful consumer choice or reinforce unnecessary anxiety about normal anatomy. Outside product marketing, Vagisil has appeared in comedy and entertainment. References to the brand have occurred in television programs, sketches, and a film, generally using its intimate-health category for humorous effect. These appearances contributed to public familiarity with the name but do not represent separate product lines or corporate ownership changes. The available reference material does not document a change in Combe's ownership of Vagisil, a public listing, a founder, or a corporate headquarters separate from Combe. The brand is therefore best described as an active Combe consumer-health brand whose principal documented development is its expansion from a topical anti-itch product into a wider external intimate-care range.

• 2021

  OMV! range launched

  [1]Vagisilen.wikipedia.org

  Vagisil expanded into scented wipes, cleansers, and anti-itch creams marketed toward teenagers and younger consumers.

• 1974

  Vagisil introduced

  [1]Vagisilen.wikipedia.org

  Combe introduced Vagisil as an American over-the-counter cream for external vulvar itching and irritation.

Accessible over-the-counter relief and personal care for external vulvar itching, irritation, hygiene, and odor concerns.

• Over-the-counter external intimate-care treatment · 1974

  Vagisil Anti-Itch Cream

  Vagisil's traditional flagship product is a topical cream intended to relieve external vulvar itching and irritation. The documented formulation contains benzocaine at 5 percent, providing local anesthetic relief from itching, and resorcinol at 2 percent, serving as an antiseptic for irritated skin. The product is positioned for accessible symptom relief rather than diagnosis or treatment of every possible cause of vulvar or vaginal discomfort.

• Intimate hygiene and personal care · 2021

  OMV!

  OMV! is a Vagisil range introduced in 2021 that includes scented wipes, cleansers, and anti-itch creams for external vulvar use. Its marketing targeted teenagers and addressed period hygiene, odor, and everyday intimate-care concerns. The range drew criticism from physicians who questioned scented intimate products and warned about irritation, allergic reactions, body shame, and delayed diagnosis of medical conditions. Vagisil stated that the products had an appropriate pH for external use and had been independently evaluated.

• 2021OMV! launch campaign

  United States

  Vagisil promoted the OMV! range to teenagers and younger consumers through messaging focused on period hygiene, odor, cleansing, and external intimate care.

  Outcome. The campaign generated substantial criticism from physicians and online commentators, while Vagisil defended the products' external-use formulation and testing.

  Source

• 2021

  Expansion into OMV! intimate careProduct launch

  Background

  Vagisil sought to extend its established anti-itch positioning into broader hygiene and personal-care needs among younger consumers.

  Action taken

  The brand launched scented wipes, cleansers, and anti-itch creams under the OMV! name and marketed them for external vulvar use.

  Aftermath

  Physicians criticized the use of scent-oriented messaging and raised concerns about irritation, shame, and delayed medical care. Vagisil responded that the products had an appropriate external-use pH and had been tested by independent dermatologists and gynecologists.

  Source

1. 1Vagisilen.wikipedia.org